List of Drugs for an Urgent Public Health Need
The List of Drugs for an Urgent Public Health Need (the List) contains the following drug-related details: the brand name, the medicinal ingredient(s), the route of administration, the strength, the dosage form and the identifying code or number, if any, assigned in the country in which the drug was authorized for sale.
The List also contains other information obtained through the public health official notification, including: the foreign regulatory authority which authorized the drug, the foreign country from which the drug can be imported, the Canadian jurisdiction notifying for the drug (i.e., the Canadian jurisdiction in which the drug is allowed to be sold), the urgent public health need for the drug, the intended use or purpose of the drug (i.e., the purpose for which the drug must be used in the Canadian jurisdiction) and the date of notification by a public health official.
A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for a period of 1 year. If a notification has not been renewed by a public health official within one year of the initial notification, the drug will no longer be eligible for importation and sale. Drugs may also be removed from the List at any time at the Minister’s discretion.
A drug is only eligible for importation and sale if all columns on the List are populated, including columns located under the “For Information Purposes” subheading.
|Brand name||Medicinal ingredient(s)||Dosage form||Strength||Route of administration||Foreign identifying code or number||For Information Purposes|
|Foreign regulatory authority / Foreign country||Canadian jurisdiction notifying for the drug||Urgent public health need||Applicable Foreign Authorised Indication (Intended use or purpose of the drug)||Date of notification by a public health official|
|Diaphin i.v.||diamorphine||Injectable||10 g/vial||Intravenous||55561||Swissmedic / Switzerland||British Columbia||Opioid crisis||Substitution therapy in case of severe heroin dependence as part of a treatment program with prescription heroin.||June 20, 2017|
|Diaphin IR 200||diamorphine||Tablet||200 mg||Oral||57724||Swissmedic / Switzerland||British Columbia||Opioid crisis||June 20, 2017|
|Diaphin SR 200||diamorphine||Tablet||200 mg||Oral||57720||Swissmedic / Switzerland||British Columbia||Opioid crisis||June 20, 2017|
|Vivitrol||naltrexone||Injectable||380 mg/vial||Intramuscular||63459-300-42||FDA / USA||British Columbia||Opioid crisis||For the prevention of relapse to opioid dependence, following opioid detoxification.||June 20, 2017|
|Probuphine||buprenorphine hydrochloride||Implant||80 mg /implant||Subdermal||58284-100-14||FDA / USA||British Columbia||Opioid crisis||For the treatment of opioid dependence in patients clinically stable on low to moderate doses of a transmucosal buprenorphine-containing product.||June 20, 2017|
|Suboxone||buprenorphine hydrochloride; naloxone hydrochloride||Film||2 mg; 0.5 mg||Buccal, Sublingual||12496-1202-3||FDA / USA||British Columbia||Opioid crisis||For the treatment of opioid dependence and as part of a complete treatment plan to include counseling and psychosocial support.||June 20, 2017|
|Suboxone||buprenorphine hydrochloride; naloxone hydrochloride||Film||8 mg; 2 mg||Buccal, Sublingual||12496-1208-3||FDA / USA||British Columbia||Opioid crisis||June 20, 2017|
|Suboxone||buprenorphine hydrochloride; naloxone hydrochloride||Film||4 mg; 1 mg||Buccal, Sublingual||12496-1204-3||FDA / USA||British Columbia||Opioid crisis||June 20, 2017|
|Suboxone||buprenorphine hydrochloride; naloxone hydrochloride||Film||12 mg; 3 mg||Buccal, Sublingual||12496-1212-3||FDA / USA||British Columbia||Opioid crisis||June 20, 2017|
|Priftin||rifapentine||Tablet||150 mg||Oral||0088-2100-24||FDA / USA||First Nations and Inuit Health Branch||Tuberculosis crisis||For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease.||June 22, 2017|
|Priftin||rifapentine||Tablet||150 mg||Oral||0088-2100-24||FDA/USA||Newfoundland/Labrador||Tuberculosis crisis||For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease.||August 8, 2017|
Report a problem or mistake on this page
- Date modified: